At the time of this episode the patient was on 50 mg of tigecycline twice daily iv, and had by that point received 53 days of tigecycline, indicating development of resistance during prolonged tigecycline therapy.
The patient returned to a single room within a general ward after 10 days on the ICU. Subsequent blood cultures were negative. Six months after initial presentation, the patient remains clinically stable. Despite prolonged admission, contact isolation prevented onward transmission of the NDM-positive bacteria within the hospital. This is the first carbapenemase-producing E. coli confirmed to be resistant to tigecycline by the national reference laboratory. An 8-fold reduction in the MIC of tigecycline for the resistant isolate when tested in the presence of the efflux inhibitor phenyl-arginine-b-naphthylamide (PAbN; at 40 mg/L) was observed (compared with only a 2-fold reduction for the susceptible isolate), which suggests up-regulated efflux as the resistance mechanism. Future studies will ascertain the specific pump(s) involved.
The isolates remained susceptible to colistin, as do most with NDM enzymes. 5, 6 This case suggests that invasive infection with NDM producers can be successfully treated with colistin, albeit with the risk of significant toxicity, and further demonstrates the emerging threat of the NDM-type metallo-b-lactamases.
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We present the case of a 40-year-old African-American female admitted with septic shock secondary to lower extremity cellulitis and acute respiratory distress syndrome with respiratory failure requiring mechanical ventilation. Her past medical history was significant for metabolic syndrome and morbid obesity (weight 230 kg and body mass index 102 kg/m 2 ). She was treated aggressively with fluid resuscitation and appropriate antimicrobial therapy, and clinically improved. On hospital day 23, she developed a fever to 38.98C. Urinalysis showed a white blood cell count of 30/high-power field (hpf) (normal¼ 0-3/ hpf) and a red blood cell count of 221/hpf (normal ¼0 -5/hpf); in addition, nitrite was negative. A complete blood count showed a significant leucocytosis of 16000 cells/mm 3 (normal ¼ 3700-9100 cells/mm 3 ), with 66% neutrophils. Urine culture was positive for Candida glabrata. Micafungin at a dose of 100 mg iv daily was initiated secondary to her compromised clinical status, with the possibility of disseminated disease and urinary tract infection diagnosis. All blood and respiratory cultures were negative. Due to her morbid obesity, the appropriateness of standard-dose micafungin was in question. Serum concentrations obtained on treatment day 5 at 4, 13 and 23 h from the start of the infusion were 2.93, 1.96 and 1.36 mg/L, respectively (Figure 1 ). She completed 2 weeks of micafungin therapy, resulting in clinical resolution and urine sterilization. The micafungin dose remained unchanged during therapy, because serum concentration data were not available until therapy was completed.
Obesity leads to multiple physiological changes in a patient, significantly altering antimicrobial pharmacokinetics. Morbidly obese patients have an increased body mass, both lean mass and adipose tissue, and increased cardiac output and blood volume, which may influence drug distribution. Changes in serum protein levels, increased renal clearance and altered hepatic metabolism impact protein binding and drug elimination. 3, 4 Micafungin is a highly protein bound, hydrophilic agent that is hepatically metabolized and excreted primarily via the faeces. 5 Micafungin is .99% bound to circulating albumin and a-1-acid-glycoprotein. In obese patients, a higher amount of micafungin may be tightly bound to serum proteins and distributed to tissues, including adipose tissue, which is 30% water, thus decreasing the micafungin exposure. Because micafungin is not highly excreted in the urine, concentrations are expected to be ,15% of serum concentrations. 5 Micafungin exhibits fungicidal activity against most Candida species in a linear dose-dependent relationship, as predicted by the AUC/MIC ratio. Pharmacokinetic analyses have demonstrated linearity in doses up to 8 mg/kg. 5 Adult subjects of normal body weight with invasive candidiasis receiving 100 mg of micafungin iv daily had average (+SD) maximum serum concentrations following a single dose and at steady-state of 5.7+2.2 and 10.1+4.4 mg/L, respectively. 5 In stem cell transplant (SCT) recipients, Hiemenz et al. 6 reported maximum serum concentrations on day 1 and day 7 to be 7.1 and 22.0 mg/L, respectively. Serum concentrations at 4 h post-dose on day 7 (steady-state) were 5.5 mg/L, significantly higher than the comparable concentration (2.93 mg/L) obtained in our patient on day 5 of therapy ( Figure 1) . 6 Pharmacokinetic data from an SCT population may not be generalizable to our case patient, although comparable steady-state AUC 0 -24 has been observed in HIV-infected patients with oesophageal candidiasis and other hosts with invasive candidiasis. 5 In an analysis performed by Gumbo et al., 7 investigators found a divergence in the micafungin kinetic profile with an inflection point at a weight of 66.3 kg. Subjects with a body weight .66.3 kg had an 50% increased clearance and significantly lower AUC 0 -24 compared with subjects below this weight threshold. 7 The authors concluded that an increase in dose may be warranted to achieve a comparable AUC/MIC ratio. Although dosing recommendations for micafungin are not weight based, our patient received a dose of 0.4 mg/kg/ day, compared with an average of .1 mg/kg for the normal weight patient; translating to a 300 mg dose in our patient. Safety has been demonstrated in doses up to 8 mg/kg, with subjects receiving an average of 600 mg per dose. 8 Despite a significantly lower AUC as compared with a patient of normal weight and presumably subtherapeutic urine concentrations, our patient had favourable microbiological and clinical outcomes. This may be due to the relatively low MIC 90 (0.06 mg/L) of non-resistant C. glabrata species and, in part, to the potential for micafungin to disassociate from serum proteins and exert its antifungal activity in vivo. 9, 10 In our morbidly obese patient, serum micafungin concentrations were significantly lower than previously published steady-state concentrations in normal body weight hosts. In lieu of available micafungin serum concentrations, the enhanced clearance and significantly decreased exposure observed in obesity may prompt clinicians to consider a dosage increase in ).
obese patients with invasive disease. Further studies are warranted to establish the optimal dose, and to assess the safety and efficacy of higher micafungin doses in an obese population with invasive candidiasis.
